Andrew Lloyd

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/611511/publications.pdf

Version: 2024-02-01

419 papers	25,209 citations	9264 74 h-index	9102 144 g-index
436 all docs	436 docs citations	436 times ranked	20071 citing authors

#	Article	IF	Citations
1	The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine, 1994, 121, 953.	3.9	4,309
2	Preferential Migration of Activated CD4 ⁺ and CD8 ⁺ T Cells in Response to MIP-1Î± and MIP-1Î². Science, 1993, 260, 355-358.	12.6	724
3	Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.. Journal of Experimental Medicine, 1993, 177, 1809-1814.	8.5	697
4	Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ: British Medical Journal, 2006, 333, 575.	2.3	634
5	Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 2001, 34, 809-816.	7.3	526
6	Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes.. Journal of Experimental Medicine, 1994, 180, 203-209.	8.5	464
7	Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Trends in Immunology, 1992, 13, 169-172.	7.5	448
8	Chemokines: leucocyte recruitment and activation cytokines. Lancet, The, 1997, 349, 490-495.	13.7	446
9	Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Services Research, 2003, 3, 25.	2.2	413
10	Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Molecular Psychiatry, 2015, 20, 440-446.	7.9	371
11	Prevalence of chronic fatigue syndrome in an Australian population. Medical Journal of Australia, 1990, 153, 522-528.	1.7	356
12	The effects of female sex, viral genotype, andIL28Bgenotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 2014, 59, 109-120.	7.3	320
13	Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 6374-6378.	7.1	289
14	The Psychiatric Status of Patients with the Chronic Fatigue Syndrome. British Journal of Psychiatry, 1990, 156, 534-540.	2.8	260
15	Longitudinal study of outcome of chronic fatigue syndrome. BMJ: British Medical Journal, 1994, 308, 756-759.	2.3	242
16	Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. Journal of Leukocyte Biology, 2003, 74, 360-369.	3.3	211
17	Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection. PLoS Pathogens, 2011, 7, e1002243.	4.7	201
18	CCR5 Expression Correlates with Susceptibility of Maturing Monocytes to Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1998, 72, 830-836.	3.4	201

#	Article	IF	Citations
19	Immunologic and psychologic therapy for patients with chronic fatigue syndrome: A double-blind, placebo-controlled trial. American Journal of Medicine, 1993, 94, 197-203.	1.5	188
20	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infectious Diseases, The, 2012, 12, 408-414.	9.1	186
21	A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. American Journal of Medicine, 1990, 89, 561-568.	1.5	184
22	Immunological abnormalities in the chronic fatigue syndrome (for editorial comment, see page 117). Medical Journal of Australia, 1989, 151, 122-124.	1.7	182
23	Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychological Medicine, 2004, 34, 1289-1297.	4.5	175
24	The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine, 1992, 4, 1-5.	3.2	173
25	Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 1028-1038.	3.3	159
26	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 123-135.e2.	1.3	157
27	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	7.3	156
28	Chemokines and serpentines: the molecular biology of chemokine receptors. Journal of Leukocyte Biology, 1993, 54, 604-612.	3.3	155
29	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	14.5	152
30	Mast cell activation and migration to lymph nodes during induction of an immune response in mice.. Journal of Clinical Investigation, 1998, 102, 1617-1626.	8.2	149
31	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	4.0	147
32	Fatigue in selected primary care settings: sociodemographic and psychiatric correlates. Medical Journal of Australia, 1996, 164, 585-588.	1.7	139
33	Long-term persistence of Coxiella burnetii in the host after primary Q fever. Epidemiology and Infection, 2000, 124, 543-549.	2.1	139
34	Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. Journal of Immunology, 1996, 156, 932-8.	0.8	139
35	Can the chronic fatigue syndrome be defined by distinct clinical features?. Psychological Medicine, 1995, 25, 925-935.	4.5	134
36	The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. Journal of Biological Chemistry, 2015, 290, 25946-25959.	3.4	128

#	Article	IF	Citations
37	Long COVID and Post-infective Fatigue Syndrome: A Review. Open Forum Infectious Diseases, 2021, 8, ofab440.	0.9	128
38	WHAT IS MYALGIC ENCEPHALOMYELITIS?. Lancet, The, 1988, 331, 1286-1287.	13.7	125
39	Linking the T cell receptor to the single cell transcriptome in antigenâ€specific human T cells. Immunology and Cell Biology, 2016, 94, 604-611.	2.3	118
40	Granulocyte-Colony Stimulating Factor and Lipopolysaccharide Regulate the Expression of Interleukin 8 Receptors on Polymorphonuclear Leukocytes. Journal of Biological Chemistry, 1995, 270, 28188-28192.	3.4	116
41	<scp>HIV</scp> and coâ€infections. Immunological Reviews, 2013, 254, 114-142.	6.0	116
42	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 2012, 30, 1805-1812.	1.6	114
43	Characteristics and Treatment Outcomes among HIVâ€Infected Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2009, 48, 650-658.	5.8	109
44	Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting. Clinical Infectious Diseases, 2013, 56, 1078-1084.	5.8	109
45	Chemokines in acute anterior uveitis. Current Eye Research, 1997, 16, 1202-1208.	1.5	106
46	What is Chronic Fatigue Syndrome? Heterogeneity Within an International Multicentre Study. Australian and New Zealand Journal of Psychiatry, 2001, 35, 520-527.	2.3	106
47	CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1Î±, interleukin-8 and RANTES. European Journal of Immunology, 1995, 25, 751-756.	2.9	104
48	Reduced heart rate variability predicts poor sleep quality in a caseâ€“control study of chronic fatigue syndrome. Experimental Brain Research, 2010, 204, 71-78.	1.5	102
49	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses, 2015, 7, 5206-5224.	3.3	102
50	Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITSâ€c study. Medical Journal of Australia, 2014, 201, 326-329.	1.7	101
51	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. Clinical Infectious Diseases, 2013, 57, 1014-1020.	5.8	97
52	Outpatient Continuous Intravenous Interleukinâ€2 or Subcutaneous, Polyethylene Glycolâ€Modified Interleukinâ€2 in Human Immunodeficiency Virusâ€Infected Patients: A Randomized, Controlled, Multicenter Study. Journal of Infectious Diseases, 1998, 178, 992-999.	4.0	95
53	Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2011, 52, 803-811.	5.8	95
54	Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment.. Journal of Clinical Investigation, 1994, 94, 293-300.	8.2	92

#	Article	IF	Citations
55	Muscle strength, endurance and recovery in the post-infection fatigue syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1316-1322.	1.9	90
56	Intravenous Immunoglobulin is Ineffective in the Treatment of Patients with Chronic Fatigue Syndrome. American Journal of Medicine, 1997, 103, 38-43.	1.5	89
57	Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clinical and Experimental Immunology, 2008, 87, 76-79.	2.6	89
58	Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology, 2010, 52, 1564-1572.	7.3	88
59	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	3.9	88
60	The temporal stability and co-morbidity of prolonged fatigue: a longitudinal study in primary care. Psychological Medicine, 1999, 29, 855-861.	4.5	87
61	B-cell receptor reconstruction from single-cell RNA-seq with VDJPuzzle. Bioinformatics, 2018, 34, 2846-2847.	4.1	87
62	Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection. Cytokine, 2008, 44, 78-84.	3.2	86
63	In Vivo Production of Cytokines and Â (C-C) Chemokines in Human Recurrent Herpes Simplex Lesions--Do Herpes Simplex Virus-Infected Keratinocytes Contribute to Their Production?. Journal of Infectious Diseases, 1998, 177, 827-838.	4.0	85
64	Cytokine Polymorphisms Have a Synergistic Effect on Severity of the Acute Sickness Response to Infection. Clinical Infectious Diseases, 2008, 47, 1418-1425.	5.8	85
65	The treatment of chronic fatigue syndrome: Science and speculation. American Journal of Medicine, 1994, 96, 544-550.	1.5	84
66	If I Am in the Mood, I Enjoy It: An Exploration of Cancerâ€Related Fatigue and Sexual Functioning in Women with Breast Cancer. Oncologist, 2011, 16, 1333-1344.	3.7	84
67	Chemokine expression and leucocyte infiltration in Sjogren's syndrome. Rheumatology, 1998, 37, 779-783.	1.9	83
68	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology, 2012, 55, 1058-1069.	7.3	82
69	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfectionâ€"the InC³Study. Journal of Infectious Diseases, 2015, 212, 1407-1419.	4.0	82
70	Impaired In Vivo Immune Responses in Patients with Melancholia. British Journal of Psychiatry, 1993, 162, 651-657.	2.8	80
71	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 317-327.	8.1	80
72	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. Journal of Hepatology, 2019, 70, 839-846.	3.7	80

#	Article	IF	Citations
73	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer, 2006, 6, 240.	2.6	79
74	Mixed HCV infection and reinfection in people who inject drugsâ€"impact on therapy. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 218-230.	17.8	79
75	Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Current Eye Research, 1996, 15, 1060-1068.	1.5	76
76	Immunopathogenesis of hepatitis C virus infection. Immunology and Cell Biology, 2001, 79, 515-536.	2.3	74
77	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. European Journal of Epidemiology, 2010, 25, 143-148.	5.7	74
78	Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. European Journal of Immunology, 1998, 28, 1773-1784.	2.9	73
79	Cytomegalovirus Infection During Pregnancy With Maternofetal Transmission Induces a Proinflammatory Cytokine Bias in Placenta and Amniotic Fluid. Journal of Infectious Diseases, 2012, 205, 1305-1310.	4.0	73
80	Reduced Cardiac Vagal Modulation Impacts on Cognitive Performance in Chronic Fatigue Syndrome. PLoS ONE, 2012, 7, e49518.	2.5	72
81	A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology, 2008, 48, 374-384.	7.3	71
82	The economic impact of chronic fatigue syndrome. Medical Journal of Australia, 1992, 157, 599-601.	1.7	70
83	Cytokine Levels in Serum and Cerebrospinal Fluid in Patients with Chronic Fatigue Syndrome and Control Subjects. Journal of Infectious Diseases, 1991, 164, 1023-1024.	4.0	69
84	Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health, 2010, 10, 633.	2.9	69
85	Screening for prolonged fatigue syndromes: validation of the SOFA scale. Social Psychiatry and Psychiatric Epidemiology, 2000, 35, 471-479.	3.1	66
86	Regulation of MMPs and TIMPs by IL-1Î² during Corneal Ulceration and Infection. , 2003, 44, 2020.		66
87	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	6.5	66
88	The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. Journal of Hepatology, 2003, 38, 349-356.	3.7	64
89	Complex genetic and environmental relationships between psychological distress, fatigue and immune functioning: a twin study. Psychological Medicine, 1999, 29, 269-277.	4.5	63
90	Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. Journal of Medical Virology, 2003, 70, 617-623.	5.0	63

#	Article	IF	Citations
91	CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut, 2004, 53, 1287-1294.	12.1	63
92	Prolonged Illness after Infectious Mononucleosis Is Associated with Altered Immunity but Not with Increased Viral Load. Journal of Infectious Diseases, 2006, 193, 664-671.	4.0	63
93	Postinfective Fatigue Syndrome Is Not Associated with Altered Cytokine Production. Clinical Infectious Diseases, 2007, 45, 732-735.	5.8	63
94	Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHVâ€6 in postâ€infective fatigue syndrome. Journal of Medical Virology, 2010, 82, 1684-1688.	5.0	63
95	A Randomized, Double-Blind, Placebo-Controlled Trial of Moclobemide in Patients With Chronic Fatigue Syndrome. Journal of Clinical Psychiatry, 2000, 61, 643-648.	2.2	63
96	Balance of Pro- and Anti-Inflammatory Cytokines Correlates with Outcome of Acute Experimental Pseudomonas aeruginosa Keratitis. Infection and Immunity, 2002, 70, 2187-2197.	2.2	62
97	Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.. Aids, 2007, 21, 2112-2113.	2.2	62
98	Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. Journal of Immunology, 1994, 153, 1762-8.	0.8	62
99	Expression of TNF-Î± by human plasma cells in chronic inflammation. Journal of Leukocyte Biology, 1997, 61, 667-678.	3.3	61
100	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 2013, 57, 2124-2134.	7.3	61
101	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005â€2014: The <scp>HITS</scp>â€p study. Journal of Viral Hepatitis, 2017, 24, 733-741.	2.0	61
102	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clinical Infectious Diseases, 2017, 64, 860-869.	5.8	61
103	Are cytokines associated with neuropsychiatric syndromes in humans?. International Journal of Immunopharmacology, 1995, 17, 677-683.	1.1	60
104	Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. BMC Health Services Research, 2003, 3, 1.	2.2	60
105	Impact of sequencing depth and read length on single cell RNA sequencing data of T cells. Scientific Reports, 2017, 7, 12781.	3.3	60
106	The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. Journal of Pain and Symptom Management, 2007, 34, 126-135.	1.2	59
107	Next generation deep sequencing and vaccine design: today and tomorrow. Trends in Biotechnology, 2012, 30, 443-452.	9.3	59
108	Cognitive deficits in patients suffering from chronic fatigue syndrome, acute infective illness or depression. British Journal of Psychiatry, 1997, 171, 377-381.	2.8	58

#	Article	IF	Citations
109	Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus. BMC Infectious Diseases, 2006, 6, 15.	2.9	58
110	Changes in Toll-like Receptor (TLR)-2 and TLR4 Expression and Function but Not Polymorphisms Are Associated with Acute Anterior Uveitis. , 2007, 48, 1711.		58
111	A prospective study of hepatitis <scp>C</scp> incidence in Australian prisoners. Addiction, 2014, 109, 1695-1706.	3.3	58
112	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of Viral Hepatitis, 2019, 26, 83-92.	2.0	58
113	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Medical Journal of Australia, 2001, 174, 183-184.	1.7	57
114	Genetic associations of fatigue and other symptom domains of the acute sickness response to infection. Brain, Behavior, and Immunity, 2012, 26, 552-558.	4.1	56
115	Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunology and Cell Biology, 2007, 85, 24-32.	2.3	55
116	Fatigue and psychological distress â€“ exploring the relationship in women treated for breast cancer. European Journal of Cancer, 2004, 40, 1689-1695.	2.8	54
117	Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. Journal of Viral Hepatitis, 2011, 18, 549-561.	2.0	54
118	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	3.3	54
119	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology, 2011, 55, 76-85.	3.7	53
120	Are Chronic Fatigue and Chronic Fatigue Syndrome Valid Clinical Entities Across Countries and Health-Care Settings?. Australian and New Zealand Journal of Psychiatry, 2009, 43, 25-35.	2.3	52
121	A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics, 2016, 17, 247.	2.8	52
122	MUSCLE PERFORMANCE, VOLUNTARY ACTIVATION, TWITCH PROPERTIES AND PERCEIVED EFFORT IN NORMAL SUBJECTS AND PATIENTS WITH THE CHRONIC FATIGUE SYNDROME. Brain, 1991, , .	7.6	51
123	Transmission of hepatitis C within Australian prisons. Medical Journal of Australia, 1999, 171, 31-33.	1.7	51
124	Prevalence of Production of Virusâ€Specific Interferonâ€Î³ among Seronegative Hepatitis Câ€“Resistant Subjects Reporting Injection Drug Use. Journal of Infectious Diseases, 2004, 190, 1093-1097.	4.0	51
125	Cytokine Production and Fatigue in Patients with Chronic Fatigue Syndrome and Healthy Control Subjects in Response to Exercise. Clinical Infectious Diseases, 1994, 18, S142-S146.	5.8	49
126	The relationship between distress and the development of a primary immune response to a novel antigen. Brain, Behavior, and Immunity, 2004, 18, 65-75.	4.1	49

#	Article	IF	Citations
127	Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Research, 1996, 65, 171-178.	3.3	48
128	Immunological determinants of the outcomes from primary hepatitis C infection. Cellular and Molecular Life Sciences, 2009, 66, 733-756.	5.4	48
129	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. International Journal of Epidemiology, 2013, 42, 1649-1659.	1.9	48
130	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2021, 6, 533-546.	8.1	48
131	Sleep-Wake Behavior in Chronic Fatigue Syndrome. Sleep, 2011, 34, 671-678.	1.1	47
132	Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clinical and Experimental Immunology, 2005, 139, 411-420.	2.6	46
133	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. International Journal of Drug Policy, 2018, 54, 18-25.	3.3	46
134	Chronic Fatigue Syndrome: An Immunological Perspective. Australian and New Zealand Journal of Psychiatry, 1998, 32, 523-527.	2.3	45
135	Quantification of Hepatitis C Virus in Human Liver and Serum Samples by Using LightCycler Reverse Transcriptase PCR. Journal of Clinical Microbiology, 2002, 40, 4346-4348.	3.9	45
136	Cutting Edge: Vasoactive Intestinal Peptide Acts as a Potent Suppressor of Inflammation In Vivo byTrans-Deactivating Chemokine Receptors. Journal of Immunology, 2003, 171, 4990-4994.	0.8	45
137	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. Journal of Pain and Symptom Management, 2017, 54, 74-84.	1.2	45
138	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathogens, 2019, 15, e1007772.	4.7	45
139	Structure, genomic organization, and expression of the human interleukin-8 receptor B gene. Journal of Biological Chemistry, 1994, 269, 11065-72.	3.4	45
140	Prolonged Fatigue, Anxiety and Depression: Exploring Relationships in a Primary Care Sample. Australian and New Zealand Journal of Psychiatry, 1999, 33, 545-552.	2.3	44
141	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
142	Understanding facilitators and barriers of directâ€acting antiviral therapy for hepatitis C virus infection in prison. Journal of Viral Hepatitis, 2018, 25, 1526-1532.	2.0	44
143	Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Medical Journal of Australia, 2010, 192, 496-500.	1.7	43
144	HUMAN HERPESVIRUS 6 AND MYALGIC ENCEPHALOMYELITIS. Lancet, The, 1988, 331, 1059.	13.7	41

#	Article	IF	Citations
145	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	2.5	41
146	Role and regulation of CXC-chemokines in acute experimental keratitis. Experimental Eye Research, 2003, 76, 221-231.	2.6	40
147	Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. International Journal of Drug Policy, 2019, 72, 123-128.	3.3	40
148	Chronic fatigue syndrome: progress and possibilities. Medical Journal of Australia, 2020, 212, 428-433.	1.7	40
149	A critical role for CCL2 and CCL3 chemokines in the regulation of polymorphonuclear neutrophils recruitment during corneal infection in mice. Immunology and Cell Biology, 2007, 85, 525-531.	2.3	39
150	Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. American Journal of Medicine, 1998, 105, 7S-10S.	1.5	38
151	The Relationship between Fatigue, Psychological and Immunological Variables in Acute Infectious Illness. Australian and New Zealand Journal of Psychiatry, 1998, 32, 180-186.	2.3	38
152	Effect of pegylated interferonâ€Î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
153	A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners. PLoS ONE, 2014, 9, e87564.	2.5	38
154	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005â€“2012. Emerging Infectious Diseases, 2015, 21, 765-774.	4.3	37
155	Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. The Lancet Gastroenterology and Hepatology, 2021, 6, 391-400.	8.1	37
156	Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Medical Journal of Australia, 2000, 172, 588-591.	1.7	36
157	Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. Clinical Infectious Diseases, 2013, 57, S70-S74.	5.8	36
158	The impact of childhood trauma on psychosocial functioning and physical health in a non-clinical community sample of young adults. Australian and New Zealand Journal of Psychiatry, 2020, 54, 185-194.	2.3	36
159	Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain, 1991, 114 (Pt 1A), 85-98.	7.6	36
160	Is there immune dysfunction in depressive disorders?. Psychological Medicine, 1990, 20, 755-761.	4.5	35
161	Culture and characterisation of epithelial cells from human pterygia. British Journal of Ophthalmology, 1999, 83, 1077-1082.	3.9	35
162	Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respiratory Medicine, 2012, 106, 701-709.	2.9	35

#	Article	IF	Citations
163	Capturing the post-exertional exacerbation of fatigue following physical and cognitive challenge in patients with chronic fatigue syndrome. Journal of Psychosomatic Research, 2015, 79, 537-549.	2.6	34
164	Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene. Journal of Immunology, 1994, 153, 2524-32.	0.8	34
165	Multicentric Castleman's disease treated with antivirals and immunosuppressants. Journal of Medical Virology, 2003, 71, 399-403.	5.0	33
166	Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and Alcohol Dependence, 2010, 107, 244-249.	3.2	33
167	Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Supportive Care in Cancer, 2014, 22, 1233-1242.	2.2	33
168	Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology, 2003, 314, 630-635.	2.4	32
169	A homing selection hypothesis for T-cell trafficking. Trends in Immunology, 2000, 21, 315-317.	7.5	31
170	Transmitted/Founder Viruses Rapidly Escape from CD8 ⁺ T Cell Responses in Acute Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5478-5490.	3.4	31
171	PATHOPHYSIOLOGY OF MYALGIC ENCEPHALITIS. Lancet, The, 1987, 330, 918-919.	13.7	30
172	Eotaxin Expression by Epithelial Cells and Plasma Cells in Chronic Asthma. Laboratory Investigation, 2002, 82, 495-504.	3.7	30
173	Protective immunity against hepatitis C virus infection. Immunology and Cell Biology, 2006, 84, 239-249.	2.3	30
174	A murine model of appendicitis and the impact of inflammation on appendiceal lymphocyte constituents. Clinical and Experimental Immunology, 2007, 150, 169-178.	2.6	30
175	Herpes Simplex Virus Type 2â€“Infected Dendritic Cells Produce TNF-Î±, Which Enhances CCR5 Expression and Stimulates HIV Production from Adjacent Infected Cells. Journal of Immunology, 2015, 194, 4438-4445.	0.8	30
176	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ TÂcell responses. Cell Reports, 2022, 38, 110345.	6.4	30
177	The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut, 2010, 59, 397-404.	12.1	29
178	Concordance of CCR5 Genotypes that Influence Cell-Mediated Immunity and HIV-1 Disease Progression Rates. Journal of Infectious Diseases, 2011, 203, 263-272.	4.0	29
179	A novel assay for detection of hepatitis C virus-specific effector CD4+ T cells via co-expression of CD25 and CD134. Journal of Immunological Methods, 2012, 375, 148-158.	1.4	29
180	Chronic fatigue syndrome: current perspectives on evaluation and management. Medical Journal of Australia, 1995, 163, 314-318.	1.7	29

#	Article	IF	Citations
181	Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Scientific Reports, 2019, 9, 13300.	3.3	28
182	The Effects of Human Recombinant MIP-1Î±, MIP-1Î², and Rantes on the Chemotaxis and Adhesion of T Cell Subsets. Advances in Experimental Medicine and Biology, 1993, 351, 139-146.	1.6	28
183	A Twin Study of the Etiology of Prolonged Fatigue and Immune Activation. Twin Research and Human Genetics, 2001, 4, 94-102.	1.0	28
184	Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Clinical and Experimental Immunology, 1999, 117, 92-99.	2.6	27
185	Immune response genes in the post-Q-fever fatigue syndrome, Q fever endocarditis and uncomplicated acute primary Q fever. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 565-574.	0.5	27
186	Virological responses during treatment for recent hepatitis C virus. Aids, 2012, 26, 1653-1661.	2.2	27
187	ABUNDANT EXPRESSION OF CHEMOKINES IN MALIGNANT AND INFECTIVE HUMAN LYMPHADENOPATHIES. Cytokine, 1999, 11, 531-540.	3.2	26
188	Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders?. Medical Journal of Australia, 2009, 190, S17.	1.7	26
189	Peripheral Blood Gene Expression in Postinfective Fatigue Syndrome Following From Three Different Triggering Infections. Journal of Infectious Diseases, 2011, 204, 1632-1640.	4.0	26
190	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	5.0	26
191	Physical and mental fatigue across the menstrual cycle in women with and without generalised anxiety disorder. Hormones and Behavior, 2020, 118, 104667.	2.1	26
192	Sequencing of hepatitis C virus for detection of resistance to directâ€acting antiviral therapy: A systematic review. Hepatology Communications, 2017, 1, 379-390.	4.3	26
193	Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. Journal of Leukocyte Biology, 1996, 59, 763-768.	3.3	25
194	Acquired Immunodeficiency Syndrome (AIDS) and Sulfadiazine-Associated Acute Renal Failure. Annals of Internal Medicine, 1987, 107, 783.	3.9	24
195	Biochemical correlates of in vivo cell-mediated immune dysfunction in patients with depression: A preliminary report. International Journal of Immunopharmacology, 1995, 17, 685-690.	1.1	23
196	The role of IL-1ÃŸ in the regulation of IL-8 and IL-6 in human corneal epithelial cells during Pseudomonas aeruginosa colonization. Current Eye Research, 2001, 23, 406-414.	1.5	23
197	Gene Expression Correlates of Postinfective Fatigue Syndrome after Infectious Mononucleosis. Journal of Infectious Diseases, 2007, 196, 56-66.	4.0	23
198	Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users. Journal of Hepatology, 2014, 61, 738-745.	3.7	23

#	Article	IF	Citations
199	The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?. PLoS ONE, 2016, 11, e0162399.	2.5	23
200	A molecular transmission network of recent hepatitis C infection in people with and without <scp>HIV</scp>: Implications for targeted treatment strategies. Journal of Viral Hepatitis, 2017, 24, 404-411.	2.0	23
201	Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome. Pediatric Infectious Disease Journal, 1990, 9, 550-553.	2.0	22
202	Assignment of genes for interleukin-8 receptors (IL8R) A and B to human chromosome band 2q35. Cytogenetic and Genome Research, 1993, 63, 238-240.	1.1	22
203	Regulatory role of IL-1beta in the expression of IL-6 and IL-8 in human corneal epithelial cells during Pseudomonas aeruginosa colonization. Clinical and Experimental Ophthalmology, 2001, 29, 171-174.	2.6	22
204	What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study.. Journal of Clinical Oncology, 2010, 28, 605-605.	1.6	22
205	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. Journal of Urban Health, 2004, 81, 448-452.	3.6	21
206	Influences of Distress and Alcohol Consumption on the Development of a Delayed-Type Hypersensitivity Skin Test Response. Psychosomatic Medicine, 2004, 66, 614-619.	2.0	21
207	Polymorphisms in Toll-like receptors-2 and -4 are not associated with disease manifestations in acute Q fever. Genes and Immunity, 2007, 8, 699-702.	4.1	21
208	Impaired Hepatitis C Virus (HCV)â€“Specific Interferon-Î³ Responses in Individuals With HIV Who Acquire HCV Infection: Correlation With CD4+ T-Cell Counts. Journal of Infectious Diseases, 2012, 206, 1568-1576.	4.0	21
209	Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduction Journal, 2015, 12, 10.	3.2	21
210	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. Journal of Epidemiology and Community Health, 2015, 69, 745-752.	3.7	21
211	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clinical Infectious Diseases, 2018, 66, 20-28.	5.8	21
212	The international collaborative on fatigue following infection (COFFI). Fatigue: Biomedicine, Health and Behavior, 2018, 6, 106-121.	1.9	21
213	Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction, 2020, 115, 901-913.	3.3	21
214	B cell immunodominance in primary hepatitis C virus infection. Journal of Hepatology, 2020, 72, 670-679.	3.7	21
215	The economic impact of chronic fatigue syndrome. Medical Journal of Australia, 1992, 157, 599-601.	1.7	21
216	Autonomic hyper-vigilance in post-infective fatigue syndrome. Biological Psychology, 2010, 85, 97-103.	2.2	20

#	Article	IF	Citations
217	Measurement of neopterin, TGF-Î² 1 and ACE in the exhaled breath condensate of patients with sarcoidosis. Journal of Breath Research, 2013, 7, 046003.	3.0	20
218	Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview. Psychosomatic Medicine, 2014, 76, 379-388.	2.0	20
219	Neurocognitive disturbances associated with acute infectious mononucleosis, Ross River fever and Q fever: A preliminary investigation of inflammatory and genetic correlates. Brain, Behavior, and Immunity, 2014, 36, 207-214.	4.1	20
220	Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. PLoS ONE, 2018, 13, e0192763.	2.5	20
221	Intraepithelial DNA Immunisation with a Plasmid Encoding a Codon Optimised COPV E1 Gene Sequence, But Not the Wild-Type Gene Sequence Completely Protects against Mucosal Challenge with Infectious COPV in Beagles. Virology, 2002, 304, 451-459.	2.4	19
222	Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. Vaccine Journal, 2007, 14, 52-59.	3.1	19
223	Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity. Virus Research, 2017, 239, 43-54.	2.2	19
224	Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. Viruses, 2020, 12, 75.	3.3	19
225	Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. Pharmacogenomics, 2006, 7, 441-454.	1.3	18
226	Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology, 2012, 23, 2890-2895.	1.2	18
227	Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virusâ€infected liver correlates with local chemokine expression. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 860-869.	2.8	18
228	Delayed-type hypersensitivity skin testing: Normal values in the Australian population. International Journal of Immunopharmacology, 1995, 17, 629-634.	1.1	17
229	Maintenance of <scp>T</scp>h1 hepatitis <scp>C</scp> virus (<scp>HCV)</scp>â€specific responses in individuals with acute <scp>HCV</scp> who achieve sustained virological clearance after treatment. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1770-1781.	2.8	17
230	Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infectious Diseases, The, 2015, 15, 451-460.	9.1	17
231	INTERFERON AND MYALGIC ENCEPHALOMYELITIS. Lancet, The, 1988, 331, 471.	13.7	16
232	Molecular Biological Investigations into the Role of the NMDA Receptor in the Pathophysiology of Schizophrenia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 17-26.	2.3	16
233	Mood disturbance after infection. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1152-1164.	2.3	16
234	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	4.0	16

#	Article	IF	Citations
235	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218.	3.3	16
236	Autonomic nervous system function, activity patterns, and sleep after physical or cognitive challenge in people with chronic fatigue syndrome. Journal of Psychosomatic Research, 2017, 103, 91-94.	2.6	16
237	A research agenda for post-COVID-19 fatigue. Journal of Psychosomatic Research, 2022, 154, 110726.	2.6	16
238	Serum Cytokine Levels in Postinfective Fatigue Syndrome. Clinical Infectious Diseases, 2010, 50, 278-279.	5.8	15
239	Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney. Australian and New Zealand Journal of Public Health, 2012, 36, 351-356.	1.8	15
240	Correlates and characteristics of hepatitis <scp>C</scp> virusâ€specific <scp>T</scp>â€cell immunity in exposed uninfected highâ€risk prison inmates. Journal of Viral Hepatitis, 2013, 20, e96-106.	2.0	15
241	Understanding the Determinants of BnAb Induction in Acute HCV Infection. Viruses, 2018, 10, 659.	3.3	15
242	A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. Journal of Immunological Methods, 2019, 472, 65-74.	1.4	15
243	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	2.5	15
244	Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection*. Journal of Viral Hepatitis, 2005, 12, 125-129.	2.0	14
245	Fatigue: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007, 25, 5685-5696.	3.8	14
246	Exploration of genetically determined resistance against hepatitis <scp>C</scp> infection in highâ€risk injecting drug users. Journal of Viral Hepatitis, 2014, 21, e65-73.	2.0	14
247	Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn. Hepatology, 2014, 60, 2127-2128.	7.3	14
248	Outcomes and predictors of response from an optimised, multidisciplinary intervention for chronic fatigue states. Internal Medicine Journal, 2016, 46, 1421-1429.	0.8	14
249	Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome. Medicine and Science in Sports and Exercise, 2016, 48, 1875-1885.	0.4	14
250	Cognitive remediation training improves performance in patients with chronic fatigue syndrome. Psychiatry Research, 2017, 257, 400-405.	3.3	14
251	Phylogenetic analysis of fullâ€length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC³ Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	2.0	14
252	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infection, Genetics and Evolution, 2019, 71, 36-41.	2.3	14

#	Article	IF	Citations
253	Scaleâ€up of hepatitis C treatment in prisons is key to national elimination. Medical Journal of Australia, 2019, 210, 391.	1.7	14
254	Parasympathetic activity is reduced during slow-wave sleep, but not resting wakefulness, in patients with chronic fatigue syndrome. Journal of Clinical Sleep Medicine, 2020, 16, 19-28.	2.6	14
255	Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants. BMC Genomics, 2021, 22, 148.	2.8	14
256	â€œThat was quick, simple, and easyâ€: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. International Journal of Drug Policy, 2022, 99, 103456.	3.3	14
257	Immunity and the Pathophysiology of Chronic Fatigue Syndrome. Novartis Foundation Symposium, 1993, 173, 176-192.	1.1	14
258	Per-Event Probability of Hepatitis C Infection during Sharing of Injecting Equipment. PLoS ONE, 2014, 9, e100749.	2.5	14
259	Occult infection with hepatitis C virus: friend or foe?. Immunology and Cell Biology, 2012, 90, 763-773.	2.3	13
260	Reliability revisited: Autonomic responses in the context of everyday well-being. International Journal of Cardiology, 2013, 166, 743-745.	1.7	13
261	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study. Journal of Viral Hepatitis, 2015, 22, 708-717.	2.0	13
262	Hepatitis Câ€specific effector and regulatory <scp>CD</scp>4 Tâ€cell responses are associated with the outcomes of primary infection. Journal of Viral Hepatitis, 2016, 23, 985-993.	2.0	13
263	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016, 37, 252-258.	2.3	13
264	Tropical arthritis in Papua New Guinea: a reactive arthritis. Medical Journal of Australia, 1990, 152, 186-189.	1.7	13
265	Illness or disease? The case of chronic fatigue syndrome. Medical Journal of Australia, 2000, 172, 471-472.	1.7	12
266	A controversial consensus â€“ comment on article by Broderick et al. Journal of Internal Medicine, 2012, 271, 29-31.	6.0	12
267	Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. Journal of Clinical Microbiology, 2016, 54, 1855-1861.	3.9	12
268	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Scientific Reports, 2017, 7, 41719.	3.3	12
269	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. International Journal of Drug Policy, 2020, 77, 102693.	3.3	12
270	Peripheral NF-ÎºB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-ÎºB kinases. Translational Psychiatry, 2022, 12, 21.	4.8	12

#	Article	IF	Citations
271	Comment on â€œDetection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndromeâ€•. Science, 2010, 328, 825-825.	12.6	11
272	Enhancing hepatitis C treatment in the custodial setting: a national roadmap. Medical Journal of Australia, 2014, 200, 15-16.	1.7	11
273	The long wait for a breakthrough in chronic fatigue syndrome. BMJ, The, 2015, 350, h2087-h2087.	6.0	11
274	Neurocognitive improvements after best-practice intervention for chronic fatigue syndrome: Preliminary evidence of divergence between objective indices and subjective perceptions. Comprehensive Psychiatry, 2016, 66, 166-175.	3.1	11
275	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal of Clinical Virology, 2016, 74, 66-72.	3.1	11
276	Analysis of resistanceâ€•associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	2.0	11
277	Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection. Journal of Infectious Diseases, 2019, 219, 1430-1438.	4.0	11
278	Single molecule, near full-length genome sequencing of dengue virus. Scientific Reports, 2020, 10, 18196.	3.3	11
279	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clinical Infectious Diseases, 2022, 75, 1809-1819.	5.8	11
280	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1990, 153, 530-534.	1.7	10
281	Expression of macrophage migration inhibitory factor during Pseudomonas keratitis. Clinical and Experimental Ophthalmology, 2001, 29, 179-182.	2.6	10
282	Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. Journal of Clinical Immunology, 2011, 31, 1079-1083.	3.8	10
283	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Journal of Viral Hepatitis, 2015, 22, 1020-1032.	2.0	10
284	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug and Alcohol Dependence, 2016, 169, 156-162.	3.2	10
285	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virology Journal, 2016, 13, 32.	3.4	10
286	Contribution of individual psychological and psychosocial factors to symptom severity and time-to-recovery after naturally-occurring acute infective illness: The Dubbo Infection Outcomes Study (DIOS). Brain, Behavior, and Immunity, 2019, 82, 76-83.	4.1	10
287	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. Frontiers in Cellular and Infection Microbiology, 2019, 9, 91.	3.9	10
288	The Invisible Burden of Chronic Fatigue in the Community: a Narrative Review. Current Rheumatology Reports, 2019, 21, 5.	4.7	10

#	Article	IF	Citations
289	Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis. PLoS ONE, 2021, 16, e0245896.	2.5	10
290	Prolonged fatigue, anxiety and depression: exploring relationships in a primary care sample. Australian and New Zealand Journal of Psychiatry, 1999, 33, 545-552.	2.3	10
291	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10
292	RED BLOOD CELL MORPHOLOGY IN CHRONIC FATIGUE SYNDROME. Lancet, The, 1989, 334, 217.	13.7	9
293	Immunological and Psychological Dysfunction in Patients Receiving Immunotherapy for Chronic Fatigue Syndrome. Australian and New Zealand Journal of Psychiatry, 1992, 26, 249-256.	2.3	9
294	Correlation of psycho-neuroendocrine-immune (PNI) gene expression with symptoms of acute infectious mononucleosis. Brain Research, 2006, 1068, 1-6.	2.2	9
295	Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a twoâ€centre, masked, caseâ€“control study. Journal of Viral Hepatitis, 2013, 20, 725-728.	2.0	9
296	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. PLoS ONE, 2013, 8, e80003.	2.5	9
297	A Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infection. BioMed Research International, 2014, 2014, 1-12.	1.9	9
298	Hepatitis B immunity in Australia: a comparison of national and prisoner population serosurveys. Epidemiology and Infection, 2015, 143, 2813-2821.	2.1	9
299	Hepatitis C in Australian prisons: a national needs assessment. International Journal of Prisoner Health, 2016, 12, 3-16.	0.9	9
300	Cluster of invasive Mycobacteria chimaera infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacement. Internal Medicine Journal, 2018, 48, 1514-1520.	0.8	9
301	Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. Journal of Virology, 2019, 93, .	3.4	9
302	Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates. Vaccine, 2020, 38, 3255-3260.	3.8	9
303	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. Brain, Behavior, & Immunity - Health, 2021, 10, 100189.	2.5	9
304	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToPâ€€ Treatment as Prevention Study in Prisons. Hepatology, 2021, 74, 2366-2379.	7.3	9
305	ANTIBODIES TO HIV ARE PRODUCED WITHIN THE CENTRAL NERVOUS SYSTEM OF ALL SUBJECTS WITH ALL CATEGORIES OF HIV INFECTION. Australian and New Zealand Journal of Medicine, 1988, 18, 854-860.	0.5	8
306	Chronic fatigue syndrome and depression. Lancet, The, 1991, 337, 922-923.	13.7	8

#	Article	IF	Citations
307	To exercise or not to exercise in chronic fatigue syndrome? No longer a question. Medical Journal of Australia, 2004, 180, 437-438.	1.7	8
308	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies,PEHRG214, in HIV-1–Infected Individuals. HIV Clinical Trials, 2004, 5, 91-98.	2.0	8
309	Does genotype mask the relationship between psychological factors and immune function?. Brain, Behavior, and Immunity, 2005, 19, 147-152.	4.1	8
310	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	3.1	8
311	Gene Expression in Response to Exercise in Patients with Chronic Fatigue Syndrome: A Pilot Study. Frontiers in Physiology, 2016, 7, 421.	2.8	8
312	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 2016, 36, 1774-1782.	3.9	8
313	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	2.3	8
314	Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. Current Medical Research and Opinion, 2020, 36, 609-611.	1.9	8
315	Immunological and Psychological Dysfunction in Patients Receiving Immunotherapy for Chronic Fatigue Syndrome. Australian and New Zealand Journal of Psychiatry, 1992, 26, 249-256.	2.3	7
316	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 27-35.	2.3	7
317	A Preliminary Study to Determine the Effect of an Infusion of Cryopreserved Autologous Lymphocytes on Immunocompetence and Viral Load in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 17, 129-136.	0.3	7
318	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clinical Infectious Diseases, 2020, 70, 123-131.	5.8	7
319	A STUDY OF ARTHRITIS IN PAPUA NEW GUINEA. Australian and New Zealand Journal of Medicine, 1988, 18, 807-808.	0.5	6
320	Summary of Public Policy and Chronic Fatigue Syndrome: A Perspective. Clinical Infectious Diseases, 1994, 18, S163-S165.	5.8	6
321	Immune Function in Chronic Fatigue Syndrome and Depression. BioDrugs, 1994, 2, 84-88.	0.7	6
322	Promoter Analysis of the Human Interleukin-8 Receptor Genes, IL-8RA and IL-8RB. Immunobiology, 1995, 193, 334-340.	1.9	6
323	How Does Patientsâ€™ Quality of Life Guide Their Preferences Regarding Aspects of Asthma Therapy?. Patient, 2008, 1, 309-316.	2.7	6
324	The natural history of acute Q fever: a prospective Australian cohort. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 661-668.	0.5	6

#	Article	IF	Citations
325	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	1.0	6
326	Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. Supportive Care in Cancer, 2017, 25, 2871-2879.	2.2	6
327	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. Journal of Medical Virology, 2018, 90, 120-130.	5.0	6
328	S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION. Schizophrenia Bulletin, 2019, 45, S318-S318.	4.3	6
329	A latent class approach to identify multiâ€risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. Journal of the International AIDS Society, 2019, 22, e25222.	3.0	6
330	Genomic variability of withinâ€host hepatitis C variants in acute infection. Journal of Viral Hepatitis, 2019, 26, 476-484.	2.0	6
331	The role of social capital in facilitating hepatitis C treatment scaleâ€up within a treatmentâ€asâ€prevention trial in the male prison setting. Addiction, 2021, 116, 1162-1171.	3.3	6
332	Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection. Journal of Immunological Methods, 2021, 495, 113087.	1.4	6
333	Chronic fatigue syndrome: an immunological perspective. Australian and New Zealand Journal of Psychiatry, 1998, 32, 523-527.	2.3	6
334	Interleukin-17 contributes to Ross River virus-induced arthritis and myositis. PLoS Pathogens, 2022, 18, e1010185.	4.7	6
335	Stromelysin (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase (TIMP-1) mRNA expression in scleritis. Ocular Immunology and Inflammation, 1995, 3, 181-194.	1.8	5
336	Characterisation of the cytokine milieu associated with the upâ€regulation of <scp>IL</scp>â€6 and suppressor of cytokine 3 in chronic hepatitis C treatment nonâ€responders. Liver International, 2015, 35, 463-472.	3.9	5
337	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 465-465.	1.0	5
338	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. BMC Infectious Diseases, 2016, 16, 241.	2.9	5
339	Randomised controlled trial of online continuing education for health professionals to improve the management of chronic fatigue syndrome: a study protocol. BMJ Open, 2017, 7, e014133.	1.9	5
340	The severity of the pathogen-induced acute sickness response is affected by polymorphisms in genes of the NLRP3 inflammasome pathway. Brain, Behavior, and Immunity, 2021, 93, 186-193.	4.1	5
341	Human CD8 Tâ€stem cell memory subsets phenotypic and functional characterization are defined by expression of CD122 or CXCR3. European Journal of Immunology, 2021, 51, 1732-1747.	2.9	5
342	Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses, 2021, 13, 983.	3.3	5

#	Article	IF	Citations
343	Chronic fatigue syndrome: current concepts of pathogenesis and treatment. Current Clinical Topics in Infectious Diseases, 1999, 19, 135-59.	0.3	5
344	Acute Q Fever and Brachial Neuritis: Case Report and Literature Review. Infection, 2002, 30, 400-402.	4.7	4
345	Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. Health Outcomes Research in Medicine, 2012, 3, e153-e167.	0.6	4
346	Evidence that hepatitis C virus genome partly controls infection outcome. Evolutionary Applications, 2014, 7, 533-547.	3.1	4
347	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. Hepatology, 2016, 64, 2264-2265.	7.3	4
348	Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 2020, 4, 904-915.	4.3	4
349	Regulation of the Acute Sickness Response by the P2RX7 Receptor. Journal of Infectious Diseases, 2021, 224, 914-920.	4.0	4
350	Subjective sleep quality and characteristics across the menstrual cycle in women with and without Generalized Anxiety Disorder. Journal of Psychosomatic Research, 2021, 148, 110570.	2.6	4
351	Violence and hepatitis C transmission in prisonâ€"A modified social ecological model. PLoS ONE, 2020, 15, e0243106.	2.5	4
352	Recurrent fever in SjâŠ˜gren's syndrome. Medical Journal of Australia, 1989, 151, 163-167.	1.7	3
353	BLOOD CELL MORPHOLOGY IN CHRONIC FATIGUE SYNDROME. Lancet, The, 1989, 334, 805.	13.7	3
354	Summary: Immunologic Studies of Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1994, 18, S160-S161.	5.8	3
355	A serological reâ€evaluation of acute nonâ€A nonâ€B hepatitis from the early 1970s. Australian and New Zealand Journal of Medicine, 2000, 30, 668-674.	0.5	3
356	Neuropsychiatric symptoms and immune activation in patients with genital herpes. Acta Neuropsychiatrica, 2008, 20, 145-151.	2.1	3
357	The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection. Hepatology, 2011, 54, 1875-1879.	7.3	3
358	Natural killer cells in highly exposed hepatitis Câ€seronegative injecting drug users. Journal of Viral Hepatitis, 2016, 23, 464-472.	2.0	3
359	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study. Journal of Hepatology, 2017, 66, S274.	3.7	3
360	People in prison who inject drugs: who is trusted when it comes to information about hepatitis C?. Addiction Research and Theory, 2021, 29, 247-254.	1.9	3

#	Article	IF	Citations
361	Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. International Journal of Drug Policy, 2021, 98, 103379.	3.3	3
362	Moyamoya disease causing recurrent cerebrovascular episodes in a young adult. Medical Journal of Australia, 1987, 146, 379-381.	1.7	3
363	The management of leprosy. Medical Journal of Australia, 1987, 146, 593-599.	1.7	3
364	The role of low-income and middle-income country prisons in eliminating hepatitis C. Lancet Public Health, The, 2022, 7, e578-e579.	10.0	3
365	Cell-mediated immune function and the outcome of chronic fatigue syndrome. International Journal of Immunopharmacology, 1995, 17, 691-694.	1.1	2
366	Molecular Biology and the Major Psychoses. Australian and New Zealand Journal of Psychiatry, 1997, 31, 12-16.	2.3	2
367	Chemokine receptor expression and function in lamina propria mononuclear cells of the human colon. Gastroenterology, 2000, 118, A355.	1.3	2
368	Immunity against hepatitis C virus infection. Lancet, The, 2002, 360, 1020.	13.7	2
369	Desbuquois syndrome in three sisters with significantly different lengths of survival. American Journal of Medical Genetics, Part A, 2006, 140A, 1253-1255.	1.2	2
370	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study. Journal of Hepatology, 2018, 68, S187-S188.	3.7	2
371	Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial. Trials, 2018, 19, 371.	1.6	2
372	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. Cancer Epidemiology, 2020, 67, 101773.	1.9	2
373	CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. International Journal of Molecular Sciences, 2021, 22, 912.	4.1	2
374	A Twin Study of the Etiology of Prolonged Fatigue and Immune Activation. Twin Research and Human Genetics, 2001, 4, 94-102.	1.0	2
375	Longâ€standing fevers in a young pregnant woman. Medical Journal of Australia, 1988, 149, 382-386.	1.7	2
376	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1990, 153, 530-4.	1.7	2
377	Snake bite on the scalp with rapid onset of envenomation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 347.	1.8	1
378	The Economic Impact of Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1994, 18, S162-S162.	5.8	1

#	Article	IF	Citations
379	Chronic Fatigue Syndrome. Pharmacoeconomics, 1994, 5, 460-464.	3.3	1
380	To exercise or not to exercise in chronic fatigue syndrome?. Medical Journal of Australia, 2004, 181, 578-580.	1.7	1
381	Treatment outcomes for Indigenous and nonâ€Indigenous inmates with hepatitis C in New South Wales prisons. Medical Journal of Australia, 2013, 199, 464-464.	1.7	1
382	Erratum to â€œA Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infectionâ€• BioMed Research International, 2014, 2014, 1-2.	1.9	1
383	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infectious Diseases, 2016, 3, ofw024.	0.9	1
384	Cytokine signature in chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9435-E9435.	7.1	1
385	Severe Eosinophilic Meningoencephalitis Secondary to Suspected Neuroangiostrongyliasis with a Good Clinical Outcome. Case Reports in Infectious Diseases, 2019, 2019, 1-4.	0.5	1
386	Antiâ€envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection. Journal of Viral Hepatitis, 2020, 27, 1012-1021.	2.0	1
387	Chronic fatigue syndrome Role of psychological factors overemphasised. BMJ: British Medical Journal, 1994, 308, 1297-1301.	2.3	1
388	5.17 HIV, weight loss and wasting syndrome. Medical Journal of Australia, 1996, 164, 549-550.	1.7	1
389	Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs.. Journal of Clinical Oncology, 2010, 28, 9047-9047.	1.6	1
390	Recurrent fever in SjÃ¸gren's syndrome. Medical Journal of Australia, 1989, 151, 163-4, 166-7.	1.7	1
391	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1991, 154, 220-220.	1.7	0
392	VIP desensitizes chemokine receptors and impairs leukocyte trafficking and inflammation in vivo. Gastroenterology, 2000, 118, A357.	1.3	0
393	Reply to A. Giacalone et al. Journal of Clinical Oncology, 2012, 30, 4175-4176.	1.6	0
394	Paradoxical Embolus and Endophthalmitis. Ophthalmology, 2012, 119, 424-424.e1.	5.2	0
395	Apology. Journal of Internal Medicine, 2013, 273, 628-628.	6.0	0
396	Regulation of <scp>T</scp> cell recruitment and inflammation in the human immunodeficiency virus/hepatitis <scp>C</scp> virus coinfected liver. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1535-1543.	2.8	0

#	Article	IF	Citations
397	Immunopathogenesis of HIV Coinfections. , 2014, , 1-15.		0
398	Co-evolving mutations in hepatitis C virus in the context of immune escape against neutralising antibody responses - A bioinformatic workflow for the analysis of co-evolving mutations in viral genomes. , 2015, , .		0
399	Physical Activity And Sleep Patterns Following Physical And Cognitive Challenge In Patients With Chronic Fatigue Syndrome.. Medicine and Science in Sports and Exercise, 2015, 47, 58.	0.4	0
400	Recommandations pour la prise en charge de lâ€™infection par le virus de lâ€™hÃ©patite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	3.3	0
401	Recomendaciones para el manejo de la infecciÃ³n por el virus de la hepatitis C entre usuarios de drogas por vÃa parenteral. International Journal of Drug Policy, 2015, , 101671.	3.3	0
402	Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005â€“2014: the HITS-p study. Journal of Hepatology, 2017, 66, S488.	3.7	0
403	A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit. Journal of Hepatology, 2017, 66, S495.	3.7	0
404	Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance. Journal of Hepatology, 2017, 66, S323.	3.7	0
405	[P3â€“225]: SYSTEMATIC REVIEW OF ASSOCIATIONS BETWEEN BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA AND CYTOKINES. Alzheimer's and Dementia, 2017, 13, P1024.	0.8	0
406	A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING. Journal of the Canadian Association of Gastroenterology, 2018, 1, 278-280.	0.3	0
407	107. Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation. Biological Psychiatry, 2019, 85, S44-S45.	1.3	0
408	Response to Commentary: â€˜Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, and Chronic Fatigue: Three Distinct Entities Requiring Complete Different Approachesâ€™. Current Rheumatology Reports, 2019, 21, 22.	4.7	0
409	Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study. Canadian Journal of Addiction, 2009, 1, 33.	0.4	0
410	Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.. Journal of Clinical Oncology, 2012, 30, 211-211.	1.6	0
411	Fatigue after infection: aetiology and pathophysiology. Microbiology Australia, 2013, 34, 142.	0.4	0
412	Immunological abnormalities in the chronic fatigue syndrome. Medical Journal of Australia, 1990, 152, 51-52.	1.7	0
413	Exacerbation of Fatigue following Interval and Continuous Exercise in Patients with Chronic Fatigue Syndrome. Medicine and Science in Sports and Exercise, 2014, 46, 684.	0.4	0
414	Chronic Fatigue and Postinfective Fatigue Syndromes. , 0, , 371-384.		0

#	Article	IF	Citations
415	Capturing Activity Pacing in People with Chronic Fatigue Syndrome Using Actigraphy. Medicine and Science in Sports and Exercise, 2016, 48, 118.	0.4	0
416	Unravelling the complexities of virus and host interactions in the Viral Immunology Systems Program, NHMRC, ACH2, National Institutes of Health. Impact, 2017, 2017, 34-36.	0.1	0
417	Immunopathogenesis of HIV Coinfections. , 2018, , 1083-1096.		0
418	Immigrant health screening. Medical Journal of Australia, 1987, 146, 609-609.	1.7	0
419	Evolution of within-host variants of the hepatitis C virus. Infection, Genetics and Evolution, 2022, 99, 105242.	2.3	0